ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Lopotová and his colleagues testified the more complex relationship of miR-451 and BCR-ABL, suggesting that miR-451 might be a putative predictor marker of Imatinib therapy response in chronic myeloid leukemia [40].